• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Shineco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    6/20/25 9:39:18 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SISI alert in real time by email
    false 0001300734 0001300734 2025-06-16 2025-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES AND EXCHANGE ACT OF 1934

     

    Date of report (date of earliest event reported): June 16, 2025

     

    SHINECO, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-37776   52-2175898
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    Room 1707, Block D, Modern City SOHO,

    No. 88, Jianguo Road, Chaoyang District,
    Beijing, People’s Republic of China, 100022

    (Address of principal executive offices)

     

    Registrant’s telephone number, including area code: (+86) 10-87227366

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each Class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   SISI   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    On June 16, 2025, Shineco Inc. (the “Company”) received a staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. Furthermore, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period, since the Company has effected a reverse stock split over the prior one-year period. The Company’s securities will be suspended from trading on The Nasdaq Capital Market at the opening of business on June 25, 2025, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market (the “Suspension”), unless the Company requests an appeal of such determination to Nasdaq’s Hearings Panel (the “Panel”) by June 23, 2025.

     

    The Company’s operations or trading are not affected by the receipt of the Letter. The Company will be submitting a hearing request form to appeal timely Nasdaq’s determination to the Panel, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. The Company’s hearing request will stay the Suspension and any further delisting actions, pending a Hearing or any additional time permitted by the Hearings Panel.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Shineco, Inc.
         
    Date: June 20, 2025 By: /s/ Jennifer Zhan
       

    Jennifer Zhan, Chief Executive Officer

     

     

     

    Get the next $SISI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SISI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SISI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Huang Shanchun claimed ownership of 5,041,667 shares (SEC Form 3)

      3 - SHINECO, INC. (0001300734) (Issuer)

      4/24/25 4:05:15 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Yan Chi Keung

      3 - SHINECO, INC. (0001300734) (Issuer)

      12/7/23 4:10:17 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Wang Xiaohui

      3 - SHINECO, INC. (0001300734) (Issuer)

      12/7/23 4:10:16 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    SEC Filings

    See more
    • SEC Form DEF 14C filed by Shineco Inc.

      DEF 14C - SHINECO, INC. (0001300734) (Filer)

      7/15/25 9:00:11 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - SHINECO, INC. (0001300734) (Filer)

      7/9/25 4:05:57 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form PRE 14C filed by Shineco Inc.

      PRE 14C - SHINECO, INC. (0001300734) (Filer)

      7/3/25 11:15:02 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Management Confidence: Shineco Executives Launch up to $2M Open-Market Stock Purchase Program

      BEIJING, June 11, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, today announced that Ms. Jennifer Zhan, the Company's chief executive officer, and Mr. Sam Wang, the Company's chief financial officer, will jointly initiate a stock purchase program (the "Stock Purchase Program") to purchase up to $2,000,000 of the Company's common stock, par value $0.001 per share (the "Common Stock") at a price of up to $1.50 per share, reflecting their strong beliefs that the Common Stock is undervalued. Under the Stock Purchase Program, purchases of the Common Stock will be made i

      6/11/25 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco's Subsidiary InfiniClone Partners with Total World Marketing for Entry into the Southeast Asian Healthcare Market

      BEIJING, May 13, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, today announced that InfiniClone Limited ("InfiniClone"), Shineco's majority-owned subsidiary in which the Company acquired a 51% equity interest on April 25, 2025, has officially launched its Southeast Asian market expansion strategy as it has reached a strategic distribution agreement with Total World Marketing (Thailand) ("TWM"), pursuant to which TWM will be responsible for the promotion and sale of InfiniClone's molecular detection kits and InfiniClone's Purelix series health products in the Southea

      5/13/25 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Announces Acquisition of Singapore Evolutionary Stem Cell Company

      Expanding the Frontiers of Regenerative Medicine BEIJING, April 23, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on April 22, 2025, its subsidiary, Shineco Life Sciences Group Hong Kong Limited ("Shineco Life Sciences"), entered into a Share Purchase Agreement (the "SPA") with Dr. Lim Kah Meng (the "Seller") to acquire 51% of the equity interest in InfiniClone Limited, a company incorporated under the laws of Hong Kong that has been wholly owned held by Dr. Lim ("InfiniClone"). InfiniClone is a biotechnology company focusing on the field of re

      4/23/25 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    Leadership Updates

    Live Leadership Updates

    See more
    • Future FinTech Announces the Appointment of Hu Li as the New CEO

      NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Future Fintech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"), a comprehensive financial and digital technology service provider, today announced that its Board of Directors (the "Board") approved the appointment of Mr. Hu Li as Chief Executive Officer ("CEO"), President and a member of the Board of the Company, effective August 5, 2024. Mr. Li will be fully responsible for the operation and management of the Company, helping it to expand internationally, manage its investment and financi

      8/9/24 9:00:00 AM ET
      $FTFT
      $SISI
      Business Services
      Consumer Discretionary
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Announces the Appointment of Two New Executive Officers

      BEIJING, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of technologically advanced healthcare products and services, announced today that its Board of Directors has appointed Ms. Xiaohui Wang and Mr. Chi Keung Yan as executive officers of the Company in key leadership roles. Effective November 13, 2023, Shineco's Board of Directors appointed Ms. Xiaohui Wang as Executive President of the Company. From March 2000 to November 2013, Ms. Wang was the founder and Chairperson of Chongqing Wintus (New Star) Enterprises Group, where she was responsible for its corporate planning, supervision of the group's business in the Chongqing region,

      11/17/23 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco, Inc. Appoints Professor Qiyin Sun as Chief Medical Consultant

      BEIJING, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that the Company has appointed Professor Qiyin Sun as the Chief Medical Consultant. Professor Sun will lead the research and innovation of the Company's tumor treatment and provide technical consultation in early tumor screening and tumor radiotherapy to support the commercialization of digital tumor diagnosis and treatment. Prior to serving as the chief medical consultant at Shineco, Professor Sun was a director at Beijing Nuclear Medicine Equipment Engineering Technology R

      2/1/22 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Shineco Inc.

      SC 13G/A - SHINECO, INC. (0001300734) (Subject)

      10/25/24 2:45:17 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Shineco Inc.

      SC 13D - SHINECO, INC. (0001300734) (Subject)

      7/12/24 5:28:03 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Shineco Inc.

      SC 13G - SHINECO, INC. (0001300734) (Subject)

      8/29/23 1:26:38 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care